Skip to main content

Table 2 Univariate Analysis: Outcomes of patients with ACC based on prognostic factors

From: Clinicopathologic implications of Myb and Beta-catenin expression in adenoid cystic carcinoma

Overall survival a

N

HR*

95% CI

p-value

Myb Staining (high vs. low)

63

1.05

0.45–2.44

0.9

Myb staining (present vs. absent)

63

1.57

0.63–3.8

0.4

Myb % tumor average (continuous)

64

0.99

0.98–1.01

0.6

Myb % tumor average (high vs. low)

64

1.05

0.45–2.44

0.9

ß-catenin cytoplasmic staining

62

2.45

0.9–6.7

0.08

Age at diagnosis

64

1.03

1.0–1.1

0.03

Race

63

0.92

0.5–1.9

0.8

Sex

64

1.06

0.4–2.6

0.8

Smoking history

57

2.9

1.1–8.2

0.03

Stage at diagnosis

56

2.21

1.2–4.2

0.02

Margin status

51

1.62

0.21–12.5

0.6

Dominant pattern

56

1.64

0.6–4.4

0.3

Treatment

64

1.31

0.6–3.1

0.5

Metastasisb

 

HR*

95% CI

p-value

Myb Staining (high vs. low)

58

2.40

0.62–9.36

0.17

Myb staining (present vs. absent)

58

4.06

1.02–14.96

0.03

Myb % tumor average (continuous)

59

0.98

0.96–1.01

0.2

Myb % tumor average (high vs. low)

59

2.27

0.58–8.90

0.2

ß-cat cytoplasmic staining

57

1.35

0.39–4.67

0.64

Age at diagnosis

59

1.01

0.97–1.06

0.52

Race

58

0.36

0.08–1.57

0.18

Sex

59

0.46

0.09–2.22

0.34

Smoking history

54

0.72

0.15–3.59

0.69

Stage at diagnosis

51

1.62

0.79–3.32

0.19

Margin status

46

–

–

–

Dominant pattern

51

–

–

–

Treatment

59

1.22

0.34–4.37

0.76

Recurrencec

 

HR*

95% CI

p-value

Myb Staining (high vs. low) a

58

1.61

0.61–4.25

0.33

Myb staining (present vs. absent) b

58

1.05

0.36–3.05

0.91

Myb % tumor average (continuous)

59

1.01

0.19–1.02

0.23

Myb % tumor average (high vs. low)

59

0.50

0.18–1.36

0.16

ß-cat cytoplasmic staining c

57

1.88

0.64–5.54

0.25

Age at diagnosis

59

1.03

0.99–1.07

0.13

Race

58

1.22

0.55–2.74

0.62

Sex

59

0.43

0.14–1.35

0.15

Smoking history

54

1.99

0.67–5.95

0.22

Stage at diagnosis

51

3.31

1.02–10.69

0.04

Margin status

46

–

–

–

Dominant pattern

51

1.56

0.32,7.54

0.58

Treatment

59

1.08

0.33–3.54

0.89

  1. The N in the table is presented as a separate column because each predictor had a differential amount of missing, and thus the sample size is not consistent among models fit to assess the different associations.
  2. *: Hazard Ratios
  3. ** Follow-up information regarding overall survival, metastasis, and recurrence was missing for 9 patients, 11 patients, and 12 patients, respectively. Additionally, ß-cat staining information was unavailable for 2 patients, and Myb staining information was unavailable for 1 patient.
  4. No estimates have been presented for margin status and dominant histologic pattern. All cases of recurrence and metastasis had a positive margin status. Given the small sample size and missing patient information for dominant histologic pattern, a survival model could not be fit to accurately analyze the data to provide conclusive results.
  5. aThe average follow-up time for patients in whom overall survival was evaluated was 58.3 months, ranging from 0 to 303.1 months
  6. bThe average follow-up time for patients in whom metastasis was evaluated was 51.5 months, ranging from 0 to 262.5 months
  7. cThe average follow-up time for patients in whom overall recurrence was evaluated was 50 months, ranging from 0.07–244.5 months
Back to article page

Journal of Otolaryngology - Head & Neck Surgery

ISSN: 1916-0216

Contact us